

with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Bunge North America, Inc., Chesterfield, MO; and CPKC Ventures Corp., Kansas City, MO, have been added as a party to this venture.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and Railpulse intends to file additional written notifications disclosing all changes in membership.

On April 20, 2021, Railpulse filed its original notification pursuant to section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to section 6(b) of the Act on May 25, 2021 (86 FR 28151).

The last notification was filed with the Department on October 31, 2022. A notice was published in the **Federal Register** pursuant to section 6(b) of the Act on November 23, 2022 (87 FR 71678).

Suzanne Morris,

Deputy Director Civil Enforcement Operations, Antitrust Division.

[FR Doc. 2024-07939 Filed 4-15-24; 8:45 am]

BILLING CODE P

DEPARTMENT OF JUSTICE

Antitrust Division

Notice Pursuant to the National Cooperative Research and Production Act of 1993—The Digital Dollar Project, Inc.

Notice is hereby given that, on March 7, 2024, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* ("the Act"), The Digital Dollar Project, Inc. ("DDP") has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in membership. The notifications were filed for the purpose of extending the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Notoros, Inc., St. Louis, MO; Kaleido, Raleigh, NC; and The HBar Foundation, George Town, CAYMAN ISLANDS have been added as parties to this venture.

No other changes have been made in either the membership or planned

activity of the group research project. Membership in this group research project remains open and DDP intends to file additional written notifications disclosing all changes in membership.

On June 9, 2022, the Digital Dollar Project filed its original notification pursuant to section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to section 6(b) of the Act on August 1, 2022 (87 FR 47007).

The last notification was filed with the Department on June 8, 2023. A notice was published in the **Federal Register** pursuant to section 6(b) of the Act on August 22, 2023 (88 FR 57129).

Suzanne Morris,

Deputy Director Civil Enforcement Operations, Antitrust Division.

[FR Doc. 2024-07983 Filed 4-15-24; 8:45 am]

BILLING CODE P

DEPARTMENT OF JUSTICE

Antitrust Division

Notice Pursuant to the National Cooperative Research and Production Act of 1993—Rapid Response Partnership Vehicle

Notice is hereby given that, on January 5, 2024, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* ("the Act"), Rapid Response Partnership Vehicle ("RRPV") has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing (1) the identities of the parties to the venture and (2) the nature and objectives of the venture. The notifications were filed for the purpose of invoking the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances.

Pursuant to section 6(b) of the Act, the identities of the parties to the venture as of the date of this filing are: AATec Medical GmbH, München, GERMANY; ASELL LLC, Owings Mills, MD; Access to Advanced Health Institute, Seattle, WA; Adaptive Phage Therapeutics, Inc., Gaithersburg, MD; Advanced BioScience Laboratories, Inc., Rockville, MD; Aerium Therapeutics, Inc., Boston, MA; Alamgir Research, Inc. dba ARIScience, Wayland, MA; Alchem Laboratories Corp., Alachua, FL; Alentic Microscience, Inc., Halifax, Nova Scotia, CANADA; Altec, Inc., Natick, MA; Antiviral Technologies LLC, Dallas, TX; Apiject Systems America, Inc., Stamford, CT; Applied Materials, Inc., Santa Clara, CA; Apriori Bio, Inc.,

Cambridge, MA; Aridis Pharmaceuticals, Inc., Los Gatos, CA; AstraZeneca Pharmaceuticals LP, Wilmington, DE; Atea Pharmaceuticals, Inc., Boston, MA; Attogene, Austin, TX; BCG Federal Corp., Washington, DC; BioFire Defense LLC, Salt Lake City, UT; BioTechnique LLC, York, PA; BiotechPharma Corp., Severna Park, MD; Bioxytran, Dedham, MA; Boston Engineering Corp., Waltham, MA; BrainScope Company, Inc., Chevy Chase, MD; Brimrose Technology Corporation, Sparks, MD; BugSeq, Inc., San Francisco, CA; CAMRIS International, Bethesda, MD; CASTLEVAX, Inc., New York, NY; CUBRC, Inc., Buffalo, NY; Care Access Research LLC, Boston, MA; Cayuga Biotech, New York, NY; Cepheid, Sunnyvale, CA; ChromoLogic, Monrovia, CA; Civica, Inc., Lehi, UT; Clarivate Analytics (US) LLC, Ann Arbor, MI; CliniOps, Inc., Fremont, CA; Cocystal Pharma, Inc., Miami, FL; Codagenix, Inc., Farmingdale, NY; Concord Medical Technology Corp., Grand Forks, ND; Critical Innovations LLC, Lawndale, CA; Curia Global, Inc., Albany, NY; CyanVac LLC, Athens, GA; Delta Development Team, Inc., Tucson, AZ; Detect, Inc., Guilford, CT; Duke University, Durham, NC; Dyadic International, Inc., Jupiter, FL; Dynavax Technologies Corp., Emeryville, CA; Eagle Health Analytics LLC, San Antonio, TX; Endpoint Health, Palo Alto, CA; Esparza Pest Control and Eco-Logic Systems, Inc., Edinburg, TX; EverGlade Consulting LLC, Charleston, SC; Everest Consulting Group, Bethesda, MD; ExeVir Bio, Zwijnaarde, BELGIUM; FHI Clinical, Durham, NC; First Line Technology LLC, Fredericksburg, VA; Foamtec International Co., Ltd., Waco, TX; Foothill Scientific Associates, CA; GRIP Molecular Technologies, Inc., St. Paul, MN; GenVault, West Deptford, NJ; Generate Biomedicines, Inc., Somerville, MA; GeoVax, Inc., Smyrna, GA; Ginkgo Bioworks, Inc., Boston, MA; Global Resonance Technologies LLC, Shelburne, VT; Gritstone bio, Inc., Emeryville, CA; Healthtrek LLC, Tampa, FL; Hexagon Bio, Inc., Menlo Park, CA; ICON Government and Public Health Solutions, Inc., Blue Bell, PA; Immune Biosolutions, Sherbrooke, CANADA; ImmunityBio, Inc., Culver City, MN; Immuron, Ltd., Blackburn North, AUSTRALIA; Inflammix, Inc., Sunnyvale, CA; Integrated Pharma Services, Frederick, MD; Invivyd, Inc., Waltham, MA; Irving Burton Associates LLC, Silver Spring, MD; Island Pharmaceuticals, Ltd., Camberwell, AUSTRALIA; Iuventus Technologies, Inc., Olean, NY; JEEVA INFORMATICS